Trump's 50%-Tariff in Brazil May Hit Major State's GDP by 2.7%
The duties could affect as many as 120,000 jobs in the region and shrink the state's economy by as much as 2.7%, Freitas said at an event organized by XP Inc in Sao Paulo.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
P&G beats on earnings, warns of $1 billion tariff hit
Procter & Gamble (PG) is taking a cautious approach to the next twelve months as it navigates uncertain consumers and Trump tariffs. The company said Tuesday it will see a $1 billion hit to profits in its new fiscal year as a result of tariffs. It offered mix EPS guidance as a result, with the bottom end of the range below analyst forecasts. Shares rose slightly in pre-market trading as fourth fiscal quarter results beat estimates. P&G's earnings are being overshadowed by a surprise change atop the C-suite ahead of the results. The consumer products giant announced late Monday that Shailesh Jejurikar will succeed CEO Jon Moeller on Jan. 1, 2026. Jejurikar is currently the company's COO but has been with P&G since 1989. He has helped lead some of P&G's most important businesses around the world, notably a fabric care business led by the Tide brand. Moeller has been the CEO of P&G since November 2021. He has been with the company since 1988, holding positions such as COO and CFO before landing the top job from David Taylor. Moeller will assume the position of executive chairman of P&G. "We are not surprised as we believe Mr. Jejurikar's was the natural successor to CEO Moeller after his appointment to the COO position in October of 2021. We also think Jejurikar's experience in both developed markets and emerging market and as the CEO of global fabric care and home care gives him enough experience to lead P&G," said JP Morgan analyst Andrea Teixeira. Earnings insight: Weakness in fabric and baby products Net sales: $20.9 billion, +2% from the prior year vs. $20.82 billion estimate Organic sales growth: +2% vs. +1.75% estimate Beauty segment organic revenue growth: +1% vs. +1.6% estimate Grooming segment organic revenue growth: +1% vs. +2.46% estimate Healthcare segment organic revenue growth: +2% vs. +3.57% estimate Fabric and home care segment organic revenue growth: +1 vs. +1.76% estimate Baby, feminine, and family care segment organic revenue growth: +1% vs. +1.37% estimate Adjusted EPS: $1.48, +6% from the prior year vs. $1.42 estimate What else caught our attention: Warnings Full-year organic sales growth: 0% to +4% (estimate: +2.54%) Full-year earnings per share: $6.83 to $7.09 (estimate: $6.99) Brian Sozzi is Yahoo Finance's Executive Editor and a member of Yahoo Finance's editorial leadership team. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email
Yahoo
3 hours ago
- Yahoo
Stellantis to absorb $1.7 billion in tariff costs in back half of the year
Big Three automaker Stellantis (STLA) updated its first half financials after releasing preliminary figures last week, noting that President Trump's tariffs cost 1.5 billion euros ($1.73 billion) in 2025. Stellantis did however re-instate financial guidance for the year. Stellantis — which counts brands like Ram, Jeep, Fiat, and Alfa Romeo in its product portfolio — said it revenues in the first half of 2025 to come in at 74.3 billion euros ($86.13 billion), down 13% year over resulting in a net loss of 2.3 billion euros ($2.67 billion). Last year in the same period Stellantis reported 5.6 billion euros ($6.48 billion) in net profit. Stellantis said adjusted operating income (AOI) came in at 500 million euros ($579.6 million), with cash flows from operating activities slipping to a loss of 2.3 billion euros ($2.67 billion). With that said, Stellantis now projects new guidance for the second half of the year expects to see increased net revenues, low-single digit AOI profitability, and improved industrial free cash flow results. Stellantis said this assumes current tariff and trade rules in place as of July 29, 2025. Stellantis stock was down 4% in the pre-market. "2025 is turning out to be a tough year, but also one of gradual improvement. Signs of progress are evident when comparing H1 2025 to H2 2024, in the form of improved volumes, Net revenues, and AOI, despite intensifying external headwinds," new CEO Antonio Filosa said in a statement. Stellantis said last week that it absorbed approximately 300 million euros ($347.77 million) in tariff-related costs as well as loss of planned production in the first half of the year. Only two months ago, Stellantis selected Filosa, a 25-year veteran of the company and current Americas COO, as its new chief executive. His tenure began on June 23, with interim CEO John Elkann remaining as executive chair. Filosa has his hands full repairing the Stellantis business. For the second quarter, Stellantis said global deliveries fell to 1.447 million units from 1.537 million a year ago, down 6%. Sales tumbled in the US 25%, while the greater European region saw sales drop 6%. Stellantis has been trying to pare bloated inventories in the US with pricing incentives and production cuts, and those measures have helped. But the big question remains, at least in the US, of the effect of auto sector tariffs targeting Canada and Mexico production. Stellantis makes several vehicles in Canada and Mexico, where 25% sector tariffs apply to all imports, in addition to auto parts tariffs. Last quarter, Stellantis idled production at plants in Canada and Mexico as a result of tariffs. Read more: 5 ways to tariff-proof your finances A just-announced US-EU tariff deal could help Stellantis, but issues including unpopular vehicles and existing tariffs for Canadian and Mexican imports will still be a problem. Pras Subramanian is the lead auto reporter for Yahoo Finance. You can follow him on X and on Instagram. Sign in to access your portfolio
